New blood pressure drug found lacking

May 10, 2007

A U.S. study has determined the first of a new class of drugs designed to treat hypertension has limited effectiveness.

There are currently seven classes of drugs used to reduce blood pressure. Aliskiren (Tekturna and Rasilez) is the first of a new class of orally active anti-hypertensive drugs that works by inhibiting the enzyme rennin that can raise blood pressure.

But a review of six large-scale clinical trials of aliskiren by Jean Sealey and Dr. John Laragh of the Weill Cornell Medical College found, because of reactive renin secretion, the drug has not been any more effective than those already widely available to control hypertension.

Laragh and Sealey found in analyzing clinical trials involving more than 5,000 hypertensive patients, aliskiren was no more effective as an anti-hypertensive agent than converting enzyme inhibitors, angiotensin receptor blockers or diuretics.

The research is detailed in the May issue of the American Journal of Hypertension.

Copyright 2007 by United Press International

Explore further: FDA approves second vaccine against meningitis strain

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.